Subcutaneous anti- globulin application is a safe treatment option of immune thrombocytopenia in children

Monika M. Trebo (1) , Eva Frey (1) , Helmut Gadner (1) , Milen Minkov (1)

1 Division of Hemato-Oncology

Subcutaneous (sc) administration of anti- seems to offer the same efficacy as intravenous administration but with less side effects. Here we report our experience with sc anti- for pediatric immune thrombocytopenia (ITP). A total of 12 children with a median age of 11.2 years had been treated by sc anti-. They received a median of 2 sc anti- applications (range 1–31) with a dosage of 250–375 IE/kg body weight. Only in one out of a total of 102 single applications, a minimal and self-limited side effect (chills) had been observed. The mean platelet count was almost doubled after sc anti- ( < 0.0001). After a median follow-up of 11.4 months, all patients are alive without major bleeding and stay well. We conclude that sc anti- is not only an efficient means of treating ITP in children but is also a safe and convenient one.

Mots clés: Immune thrombocytopenia; Childhood; Anti-; Subcutaneous injection; Side-effects

Monika M. Trebo, Eva Frey, Helmut Gadner, Milen Minkov. Subcutaneous anti- globulin application is a safe treatment option of immune thrombocytopenia in children. Annals of Hematology, 2009, 89 (4), pp.415-418. ⟨10.1007/s00277-009-0848-x⟩. ⟨hal-00535099⟩